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Abstract 
 
Breast cancer is a leading cancer diagnosis among premenopausal women around the world.  
Unlike rates in postmenopausal women, incidence rates of advanced breast cancer have 
increased in recent decades for premenopausal women.  Progress in identifying contributors to 
breast cancer risk among premenopausal women has been constrained by the limited numbers of 
premenopausal breast cancer cases in individual studies and resulting low statistical power to 
subcategorize exposures or to study specific subtypes. The Premenopausal Breast Cancer 
Collaborative Group was established to facilitate cohort-based analyses of risk factors for 
premenopausal breast cancer by pooling individual-level data from studies participating in the 
United States National Cancer Institute Cohort Consortium. This paper describes the Group, 
including the rationale for its initial aims related to pregnancy, obesity, and physical activity. We 
also describe the 20 cohort studies with data submitted to the Group by June 2016.  The 
infrastructure developed for this work can be leveraged to support additional investigations. 
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Introduction 
Breast cancer is the most common cancer diagnosed among women worldwide, with an 
estimated 1.67 million cases diagnosed in 2012, accounting for a quarter of all new cancers in 
women.  Breast cancer is also the most common cancer diagnosed among women aged 15-39 
years worldwide (1). Further, breast cancer among premenopausal women often presents at more 
advanced stages (2) and, at the youngest ages, has less favorable prognosis (3) than among 
postmenopausal women.  
 
Identifying contributors to breast cancer risk in younger women is critical to prevention. In the 
United States, incidence rates of advanced breast cancer have increased among premenopausal 
women in recent decades, whereas they have consistently decreased among women 60 and older 
during the same period (4).  Accumulating evidence supports etiologic heterogeneity between 
pre- and postmenopausal breast cancer.  Several lifestyle factors, including childbirth (5), obesity 
(6), and cigarette smoking (7) have been reported to have differential associations with breast 
cancer risk before and after menopause.  Breast cancer subtypes, including those defined by gene 
expression (8), or clinical markers including estrogen receptor (ER), progesterone receptor (PR), 
or HER2/neu oncogene expression, have emerged as critical considerations for risk factor 
associations and are differentially distributed by menopausal status (9).  Investigations of breast 
cancer etiologic heterogeneity require large sample sizes to have sufficient statistical power to 
account jointly for menopausal status and tumor subtype. 
 
The Premenopausal Breast Cancer Collaborative Group (the Collaborative Group) was 
established to facilitate cohort-based analyses of risk factors for premenopausal breast cancer, 
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both overall and according to tumor characteristics. This paper describes the formation of the 
Collaborative Group, the methods used for ongoing efforts, and provides the rationale for initial 
analyses related to pregnancy, obesity, and physical activity.  The infrastructure developed to 
address these questions can support future investigations of additional potential risk factors. 
 
Collaborative Group Studies 
The National Cancer Institute (NCI) Cohort Consortium was formed to address the need for 
large-scale collaborations to pool data in cohort studies of cancer and hence to quicken the pace 
of research (http://epi.grants.cancer.gov/Consortia/cohort.html).  The Collaborative Group was 
initiated within the Cohort Consortium in 2013 by investigators at The Institute of Cancer 
Research (ICR) in London and the National Institute of Environmental Health Sciences 
(NIEHS).  The ICR and the NIEHS serve as the Data Coordinating Centers.  
 
Eligibility 
Prospective cohorts in the Cohort Consortium with at least 100 female breast cancers diagnosed 
during follow-up before age 55 and data collection at 2 or more time points (baseline and at least 
one follow-up, to allow for exposure information and menopausal status to be updated) are 
eligible to participate.   
 
Participating cohorts 
This report describes the 20 cohort studies (counting the European Prospective Investigation into 
Cancer and Nutrition, which has many cohorts within it, as a single cohort)(6, 10-28) with data 
submitted to the Collaborative Group as of June 2016.  Participating cohorts are shown in Table 
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1 and span North America, Europe, Asia, and Australia. The numbers of female participants 
from these cohorts aged <55 at enrollment ranges from 5,671 (Campaign against Cancer and 
Heart Disease) to 117,733 (Nurses’ Health Study cohort).  The cohorts were initiated as early as 
1950 (the Radiation Effects Research Foundation Life Span Study) or as recently as 2003 
(Generations and Sister Study cohorts).  All cohorts have conducted more than one round of data 
collection; however, follow-up data are not yet fully available for three cohorts. The number of 
follow-up rounds for which data have been submitted as of June 1, 2016 ranged from 1 to 16 
across cohorts. 
 
Breast cancer ascertainment 
To date, data have been received for 1,030,761 women, and include 21,766 incident invasive or 
in situ breast cancers diagnosed after study enrollment and before age 55 years (Table 2).  
Across studies, cancer diagnoses are identified by linkage with city/state/provincial/regional (10, 
12, 13, 23, 28-31) or national (11, 12, 14, 24, 26, 32, 33) population-based cancer registries, 
and/or through self-report followed by medical record review (6, 10, 11, 14, 15, 25, 34, 35).  All 
participating studies established case ascertainment procedures and published findings related to 
incident breast cancer risk prior to joining the Collaborative Group. 
 
Data exchange and harmonization 
After approval by the NCI Cohort Consortium executive committee, the aims of the proposed 
collaboration were circulated to all Consortium members in 2013. Key exposure, covariate, and 
outcome information necessary to address the initial analyses and potential confounding or effect 
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modification was identified by the Coordinating Centers.  Complete capture of all information 
across exposures is not required for participation.  
 
After confirming eligibility, a data request template is sent to cohorts that wish to participate.  
Requested exposure data include: age/year of cohort entry, length of follow-up, demographic 
characteristics (age, race/ethnicity, education, socioeconomic status), lifestyle factors (physical 
activity, anthropometric characteristics, alcohol intake, smoking information, mammography 
use), reproductive history (menarche, menstrual cycle characteristics, gravidity, parity, 
pregnancy complications, infertility, breastfeeding, hormonal medications, menopausal status), 
benign breast disease, and family history of breast cancer (Supplemental Table 1). Most 
characteristics are requested at enrollment and each follow-up, as available.  Breast cancer 
information includes age at diagnosis, stage, grade, histology, and expression of ER, PR, HER2, 
CK5/6, or EGFR.  Participating studies are asked where possible to recode their own data to fit 
the data request template to minimize the potential for error in the recoding or understanding of 
variables in their original form.  However, if this isnot possible due to programming support 
constraints or other reasons, data are sent to the Coordinating Centers in their original form with 
a study-specific contact person identified to address questions from Coordinating Center 
programmers who reformat the information to fit the standard definitions in the data request 
template.  
 
After data transfer agreements are signed between each individual study and the Coordinating 
Centers, completed datasets were transferred to the coordinating centers using secure file transfer 
protocols.  Each cohort submits their data to one of the two Coordinating Centers who are 
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responsible for data transfer and harmonization procedures.  By having two data coordinating 
sites, one located in the United States and the other in the United Kingdom, we are able to 
minimize time zone differences to facilitate rapid communication, and accommodate studies that 
are only able to send data to certain locations because of country-specific information 
governance requirements. 
 
Data harmonization procedures are standardized across Coordinating Centers. Quality control 
checks are run on each dataset to identify (i) potential data inconsistencies for each questionnaire 
round (e.g. nulliparous women reporting more than zero births), (ii) inconsistencies between 
questionnaire rounds (e.g. number of births at follow-up being lower than at baseline 
questionnaire), and (iii) implausible values. Data checking procedures are automated with a 
shared program that was run at each Coordinating Center with standardized output. Each cohort 
is contacted regarding any issues that were identified, and clarifications or updates are 
incorporated into the study-specific dataset. Where issues could not be resolved, pre-established 
recoding rules are applied to the data. When study-specific variables can not be recoded to meet 
the data template formats (e.g. age at exposure was collected in categories but a continuous 
variable was requested), differences are documented and original data are retained for potential 
future use. Once the datasets are recoded to the standardized formats, data are merged to create a 
pooled dataset containing values from all cohorts.  
 
Defining menopausal status 
A primary issue for the Collaborative Group analyses is the definition of menopausal status 
during follow-up and at diagnosis.  Menopausal status was ascertained by cohorts at each follow-
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up round for which it was available. In addition, we request at least one follow-up round after 
age 55 or breast cancer diagnosis (if available) to allow menopausal status to be defined 
retrospectively.  In analyses conducted by menopausal status we will explore different lag 
periods to determine patterns for ‘premenopausal’ or ‘perimenopausal’ breast cancer, as 
menopause can be a gradual transition.  
 
Statistical approach 
Two statistical approaches are being used to analyze the data.  We first examine study-specific 
estimates and a pooled estimate across studies using a random-effects model that weights 
estimates by the inverse of the study-specific variance (36-38). An advantage of this approach is 
that each study-specific estimate can be derived based on its own available covariates. Cochran’s 
Q statistic is used to examine statistical heterogeneity between studies by comparing a weighted 
measure of difference between individual study estimates and the pooled estimate (39, 40). We 
calculate the I2 statistic to examine the proportion of variance that is due to between-study 
heterogeneity rather than chance (41). Potential sources of heterogeneity are investigated.   
 
Maximum flexibility for confounder adjustment and assessment of effect modification can be 
achieved by pooling individual-level data across cohorts.  If homogeneity assumptions are not 
violated, we pool data into a single dataset to conduct aggregate analyses stratified by study and 
adjusted for potential confounders that are available in all included studies.   
 
In both approaches, Cox regression models are used to calculate hazard ratios (HR) and 95% 
confidence intervals (CI) for breast cancer (42). Regression models are constructed with age as 
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the time scale such that person-time is accrued from age at cohort entry until breast cancer 
diagnosis, age at last follow-up, or other exit age, whichever occurred first. Follow-up time is 
stratified by time-updated exposures obtained from follow-up questionnaires, as appropriate. We 
test the proportional hazards assumption for exposures of interest, and in case of time-varying 
associations, e.g. an interaction between attained age and the risk factor of interest, we 
investigate the addition of time-varying covariates in the model.  In pooled analyses, potential 
variation in the association between exposures and breast cancer risk according to tumor subtype 
are assessed using Cox proportional hazards regression accounting for alternative tumor subtypes 
as competing risks (43, 44).   
 
Rationale for initial aims 
 
Pregnancy  
A “dual effect” of pregnancy on breast cancer risk has been used to describe the short-term 
increase in breast cancer risk observed after childbirth followed by a long-term protective effect 
of parity.  This pattern has been reported in epidemiological studies nested within European 
population registries (45-49) and in other case-control (50-55) and cohort (56) studies.  
Observational studies have reported 1.25 to 3-fold increases in breast cancer risk for up to 10 
years after the last birth (5, 57). The magnitude of the pregnancy-related increase in breast cancer 
risk varies across studies, and may be influenced by maternal, pregnancy, or post-partum 
characteristics. Although a period of increased breast cancer risk after childbirth has been 
reported across several studies, it remains unclear whether this observation is different for, or 
limited to, specific groups defined by age (5, 50, 51), parity (45, 52, 53), oral contraceptive use 
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(58), breastfeeding practices, family history of breast cancer (48, 59), or varies by breast cancer 
subtype (55, 56, 60) or other tumor characteristics (61, 62).  
 
Women who have a first birth at an older age may have the greatest initial increase in breast 
cancer risk, and the longest interval until a protective effect appears (5, 49, 54, 63). Over the last 
50 years, more women have postponed childbirth to older ages (5); this trend may have 
contributed to the increasing advanced-stage breast cancer rates among reproductive-age women.  
Pregnancy may also have opposite effects on risks of different breast cancer subtypes. For 
example, without considering menopausal status or subtype, parity reduces overall breast cancer 
risk by ~30% (64). However, parous women have a 50-90% increased risk of basal-like or ER-
/PR- breast cancer overall (56, 65, 66).  Associations for pre- and postmenopausal breast cancer 
combined often reflect patterns among the majority postmenopausal breast cancer cases.  Our 
study will be well positioned to examine potential variation in the association between recent 
pregnancy and breast cancer subtype among premenopausal women.  Others have proposed that 
pregnancy-related increases in breast cancer risk may also be affected by the relatively greater 
influence of genetic predisposition at younger versus older ages at diagnosis (48).  In support of 
this hypothesis, at least two studies have shown stronger associations with recent birth and breast 
cancer risk among women with a mother or sister who was diagnosed with breast cancer (48, 
59). 
 
Theories to explain the transient increased risk of breast cancer after childbirth vary. High levels 
of estrogen and progesterone and the rapid expansion of breast cells during pregnancy could 
promote latent initiated tumor cells. However, breast tumors diagnosed postpartum are more 
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often at an advanced stage and are associated with lower survival compared with those diagnosed 
during pregnancy (67-69). This evidence has led to increased focus on the role of post-partum 
exposures, including lactational involution (the process that returns the mammary gland to a non-
milk producing state), as contributors to a pro-tumorigenic microenvironment that may be 
favorable for cancer cell migration and metastasis (70).  Potential adverse effects of lactational 
involution on the breast microenvironment must also be reconciled with demonstrated lower 
risks of specific tumor subtypes among parous women who breastfeed, including ER-negative or 
basal-like tumors that confer a worse prognosis (56, 65).  A better understanding of the factors 
that contribute to short-term increases in breast cancer risk after pregnancy, including potential 
variation by age, parity, oral contraceptive use, breastfeeding, family history, or tumor subtype 
could provide necessary information for refining hypotheses about carcinogenesis in 
reproductive-age women (71).  Individual studies have had insufficient statistical power or have 
lacked key information to evaluate these characteristics jointly, making the Collaborative Group 
an ideal setting in which to advance understanding of pregnancy’s role in premenopausal breast 
cancer development.  
 
BMI and other anthropometrics 
There is epidemiological evidence for higher BMI at premenopausal ages having an inverse 
association with breast cancer risk (72-75).  Higher adiposity in childhood and adolescence 
appears to be associated with a lower risk of breast cancer at both premenopausal (73, 76-78) and 
postmenopausal (77-79) ages. Whether further weight gain contributes to additional reductions in 
premenopausal breast cancer risk is not entirely clear (80, 81). A protective effect of adiposity at 
premenopausal ages is in contrast to the effect of adiposity at postmenopausal ages, with greater 
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BMI after menopause associated with higher risk of breast cancer, probably through production 
of estrogens by aromatase in adipose tissue (82).  
 
The reason for the protective effect of adiposity at premenopausal ages is unclear, although 
several hypotheses have been put forward. Fewer ovulatory cycles in heavier women, and 
consequent lower sex hormone levels, has been suggested as a potential explanation (83).  
Similarly, an effect of polycystic ovary syndrome (PCOS) has been proposed, although Nurses’ 
Health Study II data did not support this (73). To find the reasons for the inverse associations 
with premenopausal adiposity, large study populations are needed to produce stable estimates 
and to stratify by potentially explanatory factors. 
 
Few published studies have had sufficiently large numbers of premenopausal cases to produce 
age-specific estimates over a range of ages, or to explore whether risks differ by other 
explanatory factors or by breast cancer subtype. The few that stratified by established breast 
cancer risk factors such as parity have so far reported risk estimates to be similar across these 
factors (72, 78). The association between adiposity and premenopausal breast cancer has been 
reported to vary by ethnicity, with strong associations in Caucasian, but not in Asian (84) or 
African-American (85), women, and associations are possibly stronger for ER+ than ER- 
premenopausal breast cancer (73). It is not clear what level of BMI confers the highest breast 
cancer risks – one study reported a non-linear association between BMI and risk, with the highest 
risk around 24 kg/m2 (72).  
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The Collaborative Group, with its large number of cases in the pooled dataset and data on a wide 
range of risk factors, will be able to clarify the contribution of premenopausal adiposity to breast 
cancer risk, by examining which subtypes of breast cancer are affected, analyzing associations 
by exposures such as menstrual factors, and by assessing the effect of changes in adiposity over 
time. 
 
Physical activity 
Physical activity is of particular interest in that it constitutes a potentially modifiable risk factor 
for breast and other cancers. For premenopausal women, the effect of physical activity on 
reducing breast cancer risk appears to be smaller and less certain than for postmenopausal 
women (86). However, very few studies (35, 87, 88) have published prospective data for 
premenopausal breast cancer risk in relation to physical activity, whereas others have published 
by age at breast cancer (89-91) or menopausal status at study entry (92-95), or have included 
premenopausal women in their study but did not publish effect estimates for these women 
separately (96, 97).  
 
The biological mechanisms through which physical activity could exert an effect in 
premenopausal women is less clear than in postmenopausal women, but might be through an 
effect on menarche, menstrual dysfunction, cycle length, endogenous hormone levels or estrogen 
metabolism (98-100). A smaller effect of physical activity in premenopausal than 
postmenopausal women is possible because, in contrast to postmenopausal women, in whom the 
protective effect of physical activity on breast cancer risk is partly through its effect on reducing 
adiposity, adiposity in premenopausal women has a protective effect on breast cancer risk. 
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Additionally, the impact of physical activity on hormone levels might be less influential among 
premenopausal women given their high levels of circulating hormones. 
 
To aid prevention, information is needed on the type, frequency and intensity of exercise 
required to influence breast cancer risk, as well as the ages and characteristics of women for 
whom it is most effective. There might be periods of life during which physical activity has a 
higher impact than others, such as the time period between menarche and first birth (101). There 
is also emerging evidence of differential effects of activity by ethnicity, weight, parity and family 
history of breast cancer, but mostly based on data from postmenopausal women (35, 91, 102). It 
is a limitation, however, that physical activity information is collected in many different ways 
and is difficult to harmonize (103). 
 
The Collaborative Group aims to address premenopausal breast cancer risk by frequency, 
intensity, type and ages of exercise, within strata defined by factors such as BMI, family history 
of breast cancer and age at diagnosis, and to explore specific breast cancer subtypes and stages, 
on a much larger scale than previously. The information gained can be used to advise young 
women about the extent and type of exercise that can influence their breast cancer risk. 
 
Opportunities and challenges   
The Collaborative Group is an international collaboration formed to address etiological 
factors for breast cancer that may be particular to, or differ in, premenopausal or 
perimenopausal women.  By harmonizing a wide range of exposure variables across 20 
studies and developing quality assurance and analysis programs, our collaboration is in a 
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position to conduct initial analyses of pregnancy, obesity and physical activity, and to 
leverage the research infrastructure and established collaboration model for investigations of 
other risk factors. Our initial aims do not require the use of biospecimens.  However, 
biospecimens have been collected in many of the participating studies, as described in the 
Cancer Epidemiology Descriptive Cohort Database (available at 
https://cedcd.nci.nih.gov/biospecimen.aspx ) and could potentially be incorporated to 
address future hypotheses. 
 
Some limitations and challenges have emerged. As in many consortia, information from the 
participating studies in the Collaborative Group was not collected with future pooling efforts 
in mind and follow-up data are not collected at standardized intervals.  Therefore, 
harmonization efforts must identify common data elements that are collected with minimal 
levels of measurement error. Identification of these elements can be complicated by 
questionnaires and codebooks that must be translated to a common language.  
 
Another aspect of working on pooling cohorts that requires planning and forethought is the 
potential for overlap of participants between studies, for example, in Scandinavian countries 
with multiple cohorts that have wide geographic catchment areas.  Although the existence of 
national identifiers makes it theoretically possible to identify women who may contribute 
information to more than one study in a country, the logistics for obtaining approval and 
merging datasets can be prohibitive. Therefore, we have worked with study investigators to 
identify the individual cohorts within a country with the most relevant information for 
specific Collaborative Group aims, and to develop strategies for excluding specific 
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geographic regions from one cohort, but not another, where overlap of cohort catchment 
areas is known to exist.  
 
The value of cancer consortia to address scientific questions efficiently and create new 
opportunities has become increasingly recognized (104).  Conducting analyses across 
multiple studies requires ongoing communication and transparency.  Our Collaborative 
Group holds in-person working group meetings in conjunction with the NCI Cohort 
Consortium annual meeting, as well as regular telephone conferences. These meetings 
provide a forum to discuss additional hypotheses that can be addressed in the future to 
maximize the value of the created infrastructure.  The Cohort Consortium provides valuable 
coordinating and communication services and dedicated time and space through the annual 
meeting; however, other research support for data preparation, ongoing infrastructure 
development, and dedicated time for collaboration remains a challenge faced across many 
large-scale projects.  Our Collaborative Group and others continue to work to identify and 
streamline data sharing models to maximize productivity and collaborative opportunity. 
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Table 1. Characteristics of women younger than 55 years in cohorts included in the Premenopausal Breast Cancer Collaborative Group. 
Cohort Location 
Ages at 
enrollment. 
Mean (SD), 
range 
Calendar years of 
enrollment 
Baseline data 
collection 
methods 
N of data 
collection 
rounds* 
Breast 
cancer 
cases N 
Breast cancer 
ascertainment 
sources 
Cohort size 
(women <55 
years) 
N years of 
follow-up, 
mean 
(SD), 
range (<55 
years) 
Black Women’s Health 
Study (10) 
United 
States 
37.1(8.6) 
20-54 1995 
Mailed 
questionnaire 9 1,299 
Self-report and 
state registry 52,543 
12.6 (5.6) 
0-18.6 
California Teachers 
Cohort (28) 
United 
States 
40.4(7.4) 
22-54 1995-1998 
Mailed 
questionnaire 4 1,185 State registry 47,516 
11.6 (5.0) 
0.0-17.2 
Campaign against 
Cancer and Heart 
Disease (CLUE II) (13) 
United 
States 
39.6 (9.6) 
18-54 1989 
Administered 
questionnaire 6 131 State registry 5,671 
10.8 (5.4) 
0.3-26.0 
Canadian Study of 
Diet, Lifestyle, and 
Health (12) † 
Canada 44.1 (6.9) 23-54 1991-1999 
Mailed 
questionnaire 1 377 
Provincial and 
national registry 1,589 
8.1(4.7) 
0-18.6 
European Prospective 
Investigation into 
Cancer and Nutrition 
(14) ‡ 
Europe 44.2 (8.1) 19-54 1991-2000 
Self-reported / 
administered 
questionnaires 
1 2,122 
Self-report and 
national/regional 
registries 
150,291 7.5 (4.2) 0-16.6 
Etude Epidémiologique 
auprès de femmes de la 
Mutuelle Générale de 
l'Education Nationale 
(E3N) (15) 
France 46.5 (4.2) 38-54 1989-1991 
Mailed 
questionnaire 8 1,908 Self-report 72,748 
8.1 (4.2) 
0-16.4 
Generations Study (11) United Kingdom 
39.8 (9.5) 
16-54 2003-2012 
Mailed 
questionnaire 2 719 
Self-report and 
national registry 72,058 
5.4 (1.7) 
0-9.7 
Helseundersøkelsen i 
Nord-Trøndelag 
(HUNT2)(26) 
Norway 38.9 (9.7) 20-54 1995-1997 
Administered 
questionnaire 1 209 
National cancer 
registry 20,974 
10.2 (4.1) 
0.3-14.0 
Melbourne 
Collaborative Cohort 
Study (16) 
Australia 47.5 (4.4) 31-54 1990-1994 
Administered 
questionnaire 3 227 State registry 12,029 
7.3 (4.4) 
0-20.1 
New York University 
Women’s Health Study 
(19, 20) 
United 
States 
45.2(5.5) 
31-54 1984-1991 
Self-
administered 
questionnaire 
6 371 Self-report and state registry 8,757 
9.5 (5.5) 
0-23.5 
Norwegian Women 
and Cancer Study (105) Norway 
45.7 (6.0) 
31-54 1991-2007 
Mailed 
questionnaire 3 2,124 National registry 117,633 
9.0 (5.8) 
0.3-20.5 
Nurses’ Health Study 
(17) 
United 
States 
42.6 (7.1) 
29-54 1976-1978 
Mailed 
questionnaire 16 2,743 Self-report 117,730 
12.2 (7.0) 
0.1-25.5 
Nurses’ Health Study II 
(18) 
United 
States 
34.8 (4.7) 
24-44  1989-1990 
Mailed 
questionnaire 12 3,765 Self-report 116,415 
18.7 (3.7) 
0.1-23.7 
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Radiation Effects 
Research Foundation 
Life Span Study (21) 
Japan 41.3 (8.5) 18-54 1963-1993 
Administered 
or mailed 
questionnaire 
6 130 City registry 18,420 13.5 (8.5) 0.1-36.7 
Singapore Chinese 
Health Study (22) Singapore 
49.6 (3.0) 
43-54 1993-1998 
Administered 
questionnaire 2 134 
National cancer 
registry 16,056 
5.3 (3.0) 
0.3-11.5 
Sister Study (6) United States 
47.9 (4.9) 
35-54 2003-2009 
Telephone and 
written 
questionnaire 
3 679 Self-report 24,044 4.7 (2.5) 0.1-10.6 
Southern Community 
Cohort Study (23) 
United 
States 
47.3 (4.2) 
40-54 2002-2009 
Administered 
questionnaire 2 233 State registry 30,289 
5.1 (2.4) 
0.1-13.3 
Sweden Women’s 
Lifestyle and Health 
Study (27) 
Sweden 39.7 (5.8) 29-49 1991-1992 
Mailed 
questionnaire 2 1,192 National registry 49,010 
14.4 (5.3) 
0.1-21.1 
Swedish 
Mammography Cohort 
(24) 
Sweden 46.6 (4.3) 38-54 1987-1990 
Mailed 
questionnaire 2 649 National registry 34,126 
8.3 (4.3) 
0-16.6 
United States 
Radiologic 
Technologist Cohort 
(25) 
United 
States 
36.8 (7.3) 
22-54 1983-1998 
Mailed 
questionnaire 3 1,570 Self-report 62,862 
14.5 (5.6) 
0-22.8 
*contributed as of June 2016, includes baseline and each follow-up. 
† The Canadian Study of Diet, Lifestyle, and Health is the only case-cohort study.  The cohort size (N=1,589) represents the subcohort only. 
‡ The European Prospective Study into Cancer and Nutrition (EPIC) dataset does not include the French or Norwegian EPIC sites which contributed from the Etude 
Epidémiologique auprès de femmes de la Mutuelle Générale de l'Education Nationale and Norwegian Women and Cancer Study directly. 
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Table 2. Breast cancer characteristics among women younger than 55 years across the 
Premenopausal Breast Cancer Collaborative Group. 
Characteristic     Combined N  Total N studies 
                                        with data available* 
Total breast cancers diagnosed   21,766   20 (all) 
Age at diagnosis (years)       20 (all) 
<30      32    
30-39      1,245    
40-44      3,340    
45-49      7,053   
50-54                 10,096 
Extent of disease                                                                                             20 
In situ                                                   3,651 
Invasive                            17,357 
Missing                                                           758 
Estrogen receptor status                                                                                  16 
Positive                                                           9,583 
Negative                                                         3,182 
Borderline                                                       52 
Missing                                                         8,949 
Progesterone receptor status                                                                           16 
Positive                                                           7,919    
Negative                                                          3,939 
Borderline     95 
Missing                                                           9,813 
HER2/neu overexpression           11 
Positive                                                           1,093 
Negative                                                         4,808 
            Borderline     29 
Missing                                                           15,836 
*contributed as of June 2016. 
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